Online citations, reference lists, and bibliographies.

Cytoreductive Surgery And Perioperative Intraperitoneal Chemotherapy In Recurrent Ovarian Cancer

A. Tentes, O. Korakianitis, S. Kakolyris, D. Kyziridis, D. Veliovits, C. Karagiozoglou, E. Sgouridou, Konstantinos Moustakas
Published 2010 ·

Cite This
Download PDF
Analyze on Scholarcy
Share
Background and aims Cytoreductive surgery with perioperative intraperitoneal chemotherapy is another approach for recurrent ovarian cancer. The purpose of the study was to assess the feasibility and the effect of cytoreduction and perioperative intraperitoneal chemotherapy in recurrent ovarian cancer. Patients and methods Twenty-nine women with recurrent ovarian cancer underwent cytoreductive surgery. Clinical variables were correlated to morbidity, hospital mortality, recurrences, and survival. Results Complete cytoreduction was possible in 58.6%. Extensive seeding of the small bowel and distant metastases excluded the possibility of performing complete cytoreduction. Perioperative intraperitoneal chemotherapy was given in 75.9%. Morbidity and hospital mortality rates were subsequently 24.1% and 3.4%. Recurrence was recorded in 48.3%. The extent of peritoneal dissemination was an independent variable of recurrence (P = 0.014). The 5-year survival rate was 30%. The extent of peritoneal dissemination and the completeness of cytoreduction were related to survival (P <05). The completeness of cytoreduction independently influenced survival (P = 0.013). Conclusions Secondary cytoreduction with intraperitoneal chemotherapy is feasible in most women with recurrent ovarian cancer with acceptable morbidity and mortality. Complete cytoreduction is not possible if distant and unresectable metastases are present or if the small bowel is extensively seeded. Long-term survivors are patients with limited peritoneal dissemination who may undergo complete cytoreduction.
This paper references
10.1200/JCO.20.5.1248
Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.
R. Bristow (2002)
fect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer
RY Zang (2000)
10.1111/J.1525-1438.2003.13319.X
Long‐term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum
M. Look (2003)
10.1016/j.ygyno.2009.04.026
Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (A
W. Meier (2009)
10.1007/978-1-4613-1245-1_6
Surgically directed chemotherapy: heated intraperitoneal lavage with mitomycin C.
V. Fernandez-Trigo (1996)
10.1177/030089160108700302
Cytoreductive Surgery Followed by Intraperitoneal Hyperthermic Perfusion in the Treatment of Recurrent Epithelial Ovarian Cancer: A Phase II Clinical Study
M. Deraco (2001)
10.1016/s1055-3207(03)00048-6
Peritonectomy procedures.
P. Sugarbaker (1996)
10.1097/00006534-198212000-00098
The effect of antineoplastic agents on wound healing.
M. Ferguson (1982)
AGO Ovarian Committee, AGO Ovarian Study Group (AGO-OVAR): The role of surgery in recurrent ovarian cancer
J Pfisterer (2005)
10.1007/s10434-999-0727-7
Results of Treatment of 385 Patients With Peritoneal Surface Spread of Appendiceal Malignancy
P. Sugarbaker (1999)
10.1186/1477-7819-2-21
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer
P. Piso (2004)
10.1016/S0039-6109(05)70171-7
Cytoreductive surgery for ovarian cancer.
T. Randall (2001)
10.1111/J.1525-1438.2005.00430.X
The role of surgery in recurrent ovarian cancer
J. Pfisterer (2005)
10.1016/S0748-7983(03)00149-5
Pseudomyxoma peritonei: a review of 62 cases.
S. van Ruth (2003)
10.1007/s004230050246
Management of peritoneal-surface malignancy: the surgeon’s role
P. Sugarbaker (1999)
10.1007/978-1-4613-1245-1_7
Pathobiology of peritoneal carcinomatosis from ovarian malignancy.
T. A. Sugarbaker (1996)
toreductive surgery followed by intraperitoneal hyperther - mic perfusion in the treatment of recurrent epithelial ovarian cancer : a phase II clinical study
M Deraco (2001)
Secondary cytoreductive surgery in ovarian cancer.
G. Michel (1989)
10.1016/S1055-3207(03)00047-4
Management of peritoneal surface malignancy
P. Sugarbaker (2003)
10.1002/1098-2388(200007/08)19:1<62::AID-SSU10>3.0.CO;2-O
Recurrent ovarian carcinoma: is there a place for surgery?
L. Chen (2000)
Surgery for recurrent ovarian cancer.
P. Rose (2000)
10.1097/00000658-199809000-00007
Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer.
W. Yu (1998)
10.1111/IGC.0b013e3181a1c7aa
Epithelial Ovarian Cancer: Role of Pegylated Liposomal Doxorubicin in Prolonging the Platinum-Free Interval and Cancer Antigen 125 Trends During Treatment
J. Tanguay (2009)
10.1136/IJGC-00009577-200303001-00132
SECONDARY CYTOREDUCTIVE SURGERY FOR RECURRENT OVARIAN CANCER
P. Harter (2003)
10.1053/EJSO.2001.1152
Cytoreduction and intraperitoneal chemotherapy for the management of peritoneal carcinomatosis, sarcomatosis and mesothelioma.
G. Begossi (2002)
10.1111/J.1525-1438.2006.00580.X
Long‐term survival in advanced ovarian carcinoma following cytoreductive surgery with standard peritonectomy procedures
A. Tentes (2006)
Ovarian cancer: Rethinking Prognostic Factors and Chemotherapy
J Neijt (1994)
10.1200/JCO.2003.04.187
Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer.
V. Verwaal (2003)
10.1053/EJSO.2002.1380
Peritoneal cancer index: a prognostic indicator of survival in advanced ovarian cancer.
A. Tentes (2003)
10.1002/(SICI)1097-0142(20000101)88:1<144::AID-CNCR20>3.0.CO;2-X
The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma
S. Eisenkop (2000)
Advances in themanagement of epithelial ovarian cancer
S Memarzadeh (2001)
10.1016/0020-7292(90)90934-D
Secondary cytoreductive surgery for recurrent epithelial ovarian cancer
M. Morris (1990)
10.1002/1096-9098(200009)75:1<24::AID-JSO5>3.0.CO;2-L
Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer.
R. Zang (2000)
10.1006/GYNO.2001.6404
Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma.
C. Scarabelli (2001)
10.1002/cncr.23553
Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer
A. di Giorgio (2008)
10.1002/1097-0142(19951101)76:9<1606::AID-CNCR2820760917>3.0.CO;2-H
Secondary cytoreductive surgery for recurrent ovarian cancer. A prospective study
S. Eisenkop (1995)



Semantic Scholar Logo Some data provided by SemanticScholar